7月16日，百时美施贵宝盘中上涨3.01%，报60.485美元/股，成交额4.14亿美元。
消息面上，FDA于7月13日正式受理公司提交的Mezigdomide联合卡非佐米及地塞米松治疗复发或难治性多发性骨髓瘤的新药上市申请，PDUFA目标行动日期定于明年5月13日。该申请基于三期临床数据，显示联合疗法将疾病进展或死亡风险降低52%，中位无进展生存期延长至18个月。此外，RBC近期指出公司下半年将迎来Milvexian抗卒中及Cobenfy阿尔茨海默候选药物等关键里程碑，CELMoD平台价值仍被低估。制药板块今日整体走强，礼来涨1.44%，默沙东涨2.95%，强生涨1.01%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.